MMIT (Managed Markets Insight & Technology)’s Post

Payers are engaging specialty benefit management companies to help them manage high-cost, high-complexity disease states. In Fierce Pharma, MMIT’s Stephen Callahan shares the latest research and how this trend will impact pharma companies planning for market access: https://ow.ly/xUSr50SlgSl. #SpecialtyBenefitManagers #SBMs #PharmaCompanies #MarketAccess

Payers are engaging specialty benefit management companies to help them manage high-cost, high-complexity disease states. In Fierce Pharma, MMIT’s Steve Callahan shares the latest research and how this trend will impact pharma companies planning for market access: https://ow.ly/KQlo50SlgEa. #SpecialtyBenefitManagers #SBMs #PharmaCompanies #MarketAccess

🌟 Episode 4: Value Proposition 🌟 The fourth episode of our series on market access is live. In this chapter, we dive into the critical concept of Value Proposition (VP). 📊 A robust VP is essential for gaining market access, securing reimbursement, and achieving favorable listings. A well-crafted VP might include: 📌 Clinical Benefits: Improved efficacy, safety, patient outcomes... 📌 Differentiation: Unique mechanisms, innovative delivery, addressing unmet needs... 📌 Patient-Centric Benefits: Convenience, fewer side effects, better adherence... 📌 Economic Value: Cost-effectiveness, potential savings for healthcare systems... We also explore the PICO framework (Population, Intervention, Comparator, Outcomes) used by payers, especially in Europe, to assess pharmaceutical compounds. In light of the new EU regulation, understanding and addressing multiple PICOs early can streamline the Joint Clinical Assessment process. Stay tuned for more insights in our upcoming episodes and don’t forget to subscribe to my channel. #Pharma #MarketAccess #ValueProposition #PICO #Healthcare

'Drug launch excellence needs a hybrid solution, combining digital patient support with human touch services'. Katie Duncalf, MSc, talks about the benefits to Pharma of creating a successful patient support solution at the Pharmaceutical Launch Excellence Summit in London last week. She discusses the 5 key steps for a successful patient support solution: 1. Understanding the patient journey 2. Building patient support 3. Creating Connected Care with the healthcare ecosystem 4. Generating Evidence 5. Continuing to measure, optimise and evolve the programme Katie emphasises how a patient-centric approach is imperative to driving adherence and improving patient health outcomes. To find out how Sciensus can enhance your patient support solution, visit: https://lnkd.in/ecUBxiwv #Pharma #DigitalSolutions #PatientAdherence #PharmaceuticalExcellence

💡 How can pharma go beyond the pill to deliver greater value to patients and the healthcare system? Join us at the EPP Life Sciences Pricing Forum 2024 for the session "Beyond the Pill: Value-Based Services in Pharma" with Luis E. Marin from Novartis. This session will explore how partnering with pharma can improve the patient journey by adding value beyond traditional treatments. 🔍 Key Topics: - Adding value to patients and healthcare systems through innovative partnerships - Measuring efficiency and economic impact with value-based services - Real-world case studies from Spain that showcase the success of these approaches Interested in how pharma can go beyond the pill to improve patient outcomes and deliver measurable impact? Download the event brochure for full details on this session and more! https://lnkd.in/d2KYzBZX #EPP #EPPLSPF #LSF24 #LifeSciences #Pharma #Biopharma #Medtech #PricingStrategies #Innovation #Healthcare #LifeSciences2024

💡 How can the pharmaceutical industry create more value for patients and the healthcare system beyond traditional treatments? Discover the answer at the EPP Life Sciences Pricing Forum 2024! Don’t miss the session "Beyond the Pill: Value-Based Services in Pharma" led by Luis E. Marin from Novartis. 🌟 This session will delve into how pharma can enhance the patient experience by offering value beyond the medication itself. 🔍 What You'll Learn: -How innovative partnerships can deliver added value to patients and healthcare systems. -Methods to measure efficiency and economic impact through value-based services. -Real-world success stories from Spain demonstrating these approaches. Curious about how pharma can redefine patient care and drive measurable impact? Get the full details by downloading the event brochure here: https://lnkd.in/d2KYzBZX #EPP #EPPLSPF #LSF24 #LifeSciences #Pharma #Biopharma #Medtech #PricingStrategies #Innovation #Healthcare #LifeSciences2024

As part of a recent Reuters Events webinar, Ana Marija Gjurovic, MD, Global Head of Patient Engagement at AstraZeneca, highlighted a significant shift from pharma's traditional focus on healthcare professionals to actively involving patients. For more on this topic, read our article 'Empowering Patients: Transforming Drug Development through Engagement' here: https://lnkd.in/eijXA3DX #PatientCenteredCare #PharmaInnovation #CollaborativeHealthcare #PatientFirst

As a thought leader in the Real-World Evidence (RWE) space, Petauri presented the poster 'Payer Preferences Around Manufacturer Provided Evidence and Engagements in the US' at ISPOR Europe 2024. The poster represents perspectives from national and regional Managed Care Organizations (MCOs), Pharmacy Benefit Managers (PBMs), and Integrated Delivery Networks (IDNs) in the US. While sentiment regarding information provided by biopharmaceutical manufacturers varies, payers strongly value transparent and high-quality scientific evidence. Both pre- and post-launch, payers continue to be most interested in clinical efficacy and safety data, along with pricing/economic information.    Let's discuss opportunities to build upon these research findings to implement impactful market access and HEOR strategies for your brand. Please contact us at https://lnkd.in/eadTaaSM   Poster Authors: Nicole Lodowski, Bob Nordyke, Benjamin Tindall, Emily Coriale, PharmD, Joe Honcz, Sree Mangala C.   #ManagedCare #ManagedMarkets #HealthcostInsights #ISPOREurope2024 #HealthEconomics #PharmaInsights #RWE #Healthcare

I’m thrilled to share my recent research on U.S. payer preferences regarding manufacturer-provided evidence in the pharmaceutical and biotechnology industries, which was presented at ISPOR 2024! In this study, we dive deep into how payers evaluate and prioritize evidence when making formulary decisions, and the implications this has for manufacturers looking to navigate the evolving healthcare landscape. It was an honor for my organization to present these findings at ISPOR and to contribute to ongoing discussions on improving healthcare access and outcomes. I’m eager to hear your thoughts and insights on this critical topic! #Pharmaceuticals #Healthcare #ISPOR2024 #HealthEconomics #PayerResearch #Innovation #Research

Payer strategy and continual review of market access opportunities are critical to any brands long term success. Interesting read here from Petauri.